Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation

by Shannon R. McCurdy, Ephraim J. Fuchs
Published 2015-01-01

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

by Ying-Jun Chang, Leo Luznik, Ephraim J. Fuchs, Xiao-Jun Huang
Published 2016-04-01

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

by Ashley Munchel, Chimen Kesserwan, Heather J. Symons, Leo Luznik, Yvette L. Kasamon, Richard J. Jones, Ephraim J. Fuchs
Published 2011-06-01

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

by Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, Renier J Brentjens, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, John M Pagel, Martin S Tallman
Published 2020-07-01

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

by Shannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry, Javier Bolaños-Meade, Hua-Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, Ivana Gojo, B. Douglas Smith, Maria P. Bettinotti, William H. Matsui, Amy E. Dezern, Carol Ann Huff, Ivan Borrello, Keith W. Pratz, Douglas E. Gladstone, Lode J. Swinnen, Robert A. Brodsky, Mark J. Levis, Richard F. Ambinder, Ephraim J. Fuchs, Gary L. Rosner, Richard J. Jones, Leo Luznik
Published 2017-02-01